Across TCGA pan-cancer cohorts, CNOT8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CNOT8 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CNOT8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CNOT8 expression acts as an unfavorable survival marker.
ACC and LUSC are the cancer types where CNOT8 Mutation most reproducibly stratifies survival.